NCT03239145 2026-03-12Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorDana-Farber Cancer InstitutePhase 1 Completed62 enrolled 17 charts
NCT00752570 2015-09-02A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal CarcinomaAmgenPhase 2 Completed144 enrolled